Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal irinotecan + 5-fluorouracil + leucovorin + lenvatinib
- Development stage
- Unknown
- Lead developer
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination chemotherapy and targeted therapy regimen is being evaluated as a second-line treatment for advanced biliary tract cancer. It consists of liposomal irinotecan (a nanoliposomal formulation of the topoisomerase I inhibitor irinotecan), 5-fluorouracil (an antimetabolite), leucovorin (a folate analog that enhances 5-FU activity), and lenvatinib (a multi-kinase inhibitor). The regimen aims to inhibit tumor cell replication through DNA damage and metabolic disruption while simultaneously targeting angiogenesis and tumor growth pathways by inhibiting VEGFR, FGFR, and other receptor tyrosine kinases. It is currently being studied in a Phase II clinical trial sponsored by the Cancer Institute and Hospital, Chinese Academy of Medical Sciences, specifically for patients who have progressed after first-line therapy.
- Other names
- nal-IRI + 5-FU/LV + lenvatinibLiposomal irinotecan II + 5-FU + LV + lenvatinib
02
Targets
VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)TS (Thymidylate synthase)VEGFR4 (Vascular endothelial growth factor Receptor-3)PDGFRA (Platelet-derived growth factor receptor alpha)FGFR2 (Keratinocyte growth factor receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR4 (Fibroblast growth factor receptor 4)TOP1 (DNA Topoisomerase I)FGFR3 (Fibroblast growth factor receptor 3)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on liposomal irinotecan + 5-fluorouracil + leucovorin + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal irinotecan + 5-fluorouracil + leucovorin + lenvatinib.